(Q38108521)

29 August 2017

Proton pump inhibitors and potential interactions with clopidogrel: an update (English)

1 reference

29 August 2017

1 reference

Lauren B Gerson

1

1 reference

29 August 2017

1 June 2013

1 reference

Current gastroenterology reports

29 August 2017

1 reference

29 August 2017

15

1 reference

29 August 2017

6

1 reference

29 August 2017

329

1 reference

https://scigraph.springernature.com/pub.10.1007/s11894-013-0329-1

29 August 2017

0 references

cites work

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in plat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11894-013-0329-1

Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor

21 January 2018

1 reference

12 December 2020

Pharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic review

1 reference

12 December 2020

Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel.

1 reference

12 December 2020

Clinical outcomes in patients with the concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention: an analysis from the Guthrie Health Off-Label Stent (GHOST) investigators

1 reference

12 December 2020

Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.

1 reference

12 December 2020

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

1 reference

12 December 2020

Platelet function in clopidogrel-treated patients with acute coronary syndrome

1 reference

12 December 2020

A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers

1 reference

12 December 2020

Lack of significant interactions between clopidogrel and proton pump inhibitor therapy: meta-analysis of existing literature

1 reference

12 December 2020

Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention

1 reference

12 December 2020

What makes platelets angry: diabetes, fibrinogen, obesity, and impaired response to antiplatelet therapy?

1 reference

12 December 2020

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

1 reference

12 December 2020

Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry

1 reference

12 December 2020

Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors

1 reference

12 December 2020

Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.

1 reference

12 December 2020

10.1007/S11894-013-0329-1

Identifiers

DOI

1 reference

PubMed ID

23695547

Dimensions Publication ID

29 August 2017

0 references

1 reference

PubMed ID

23695547